Dr Melodie Grandin obtained a PhD fellowship from the European Laboratory of Excellence to prepare her PhD at the Cancer Research Center of Lyon (CRCL), France. There, she worked on the characterization and preclinical development of a combined therapy targeting the epigenetic disruption of the Netrin-1 dependence receptors apoptotic pathway, with a particular focus on breast and lung cancers.
Dr Grandin joined Hudson Institute in January 2018 and will investigate enhancer mediated epigenetic mechanisms in cancer, and will identify biomarkers and therapeutic vulnerabilities. She will also investigate CCAT1-SE activity and its therapeutic vulnerability for cMYC driven colorectal cancer.
Mathot P, Grandin M, Devailly G, Souaze F, Cahais V, Moran S, Campone M, Herceg Z, Esteller M, Juin P, Mehlen P, Dante R (2017) DNA methylation signal plays a major role in the response of cancer cells to the microenvironment, in human breast tumors. Oncogenesis 6:e390.
Grandin M, Mathot P, Devailly G, Bidet Y, Ghantous A, Favrot C, Gilbert B, Gadot N, Puisieux I, Herceg Z, Delcros JG, Bernet A, Mehlen P, Dante, R (2016) Inhibition of DNA methylation promotes breast tumor sensitivity to netrin-1 interference. EMBO Mol Med 8:863-877.
Grandin M*, Meier M*, Delcros JG*, Nikodemus D*, Reuten R*, Patel, TR, Goldschneider D, Orriss G, Krahn N, Boussouar A, Abes R, Dean Y, Neves D, Bernet A, Depil S, Schneiders F, Poole K, Dante R, Koch M, Mehlen P, Stetefeld J (2016) Structural Decoding of the Netrin-1/UNC5 Interaction and its Therapeutical Implications in Cancers. Cancer Cell 29:173–185. * shared first authorship
Devailly G, Grandin M, Perriaud L, Mathot P, Delcros JG, Bidet Y, Dante R (2015) Dynamics of MBD2 deposition across methylated DNA regions during malignant transformation of human mammary epithelial cells. Nucleic Acids Res 43:5838–5854.